Futura Medical PLC - Stock Quote FAMDF
Morningstar's Futura Medical PLC Stock Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Futura Medical PLC's Company Profile
Futura Medical PLC is a drug manufacturer based in the United Kingdom. It lays primary focus exclusively on topically applied pharmaceutical drugs and medical devices which are developed using a highly efficient and proprietary transdermal delivery technology, DermaSys. DermaSys is a versatile technology that can be customized to suit the specific active compound being used and the therapeutic indication. Futura's products are used mainly for the treatment of erectile dysfunction and pain relief.
Guildford, Surrey, GU2 7YG, United Kingdom